Evidence map›Paper›PMID 37461081›Full record

ReviewParasites & vectors2023

Reduced polymorphism of Plasmodium vivax early transcribed membrane protein (PvETRAMP) 11.2.

Edvige Perrotti, Mariangela L'Episcopia, Michela Menegon, Irene S Soares, Angel Rosas-Aguirre, Niko Speybroeck, Alejandro LLanos-Cuentas, Didier Menard, Marcelo Urbano Ferreira, Carlo Severini

Open access · goldAbstract readReview
In one paragraph

Review in Parasites & vectors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 6 countries.

Edvige PerrottiDepartment of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy. Edvige.perrotti@iss.it.
Mariangela L'EpiscopiaDepartment of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy.
Michela MenegonDepartment of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy.
Irene S SoaresDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Angel Rosas-AguirreResearch Institute of Health and Society (IRSS), Université Catholique de Louvain, Brussels, Belgium.
Niko SpeybroeckResearch Institute of Health and Society (IRSS), Université Catholique de Louvain, Brussels, Belgium.
Alejandro LLanos-CuentasInstituto de Medicina Tropical "Alexander Von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru.
Didier MenardLaboratoire de Parasitologie Et Mycologie Médicale, Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Marcelo Urbano FerreiraDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Carlo SeveriniDepartment of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy. Carlo.severini@iss.it.
Istituto Superiore di Sanità · ITUCLouvain · BEUniversidade de São Paulo · BRHôpitaux Universitaires de Strasbourg · FRUniversidad Peruana Cayetano Heredia · PE

Funding

Académie de Recherche et d'Enseignement Supérieur-Commission de la Coopération au Développement of Belgium ARES-CCDAcadémie de Recherche et d'Enseignement Supérieur-Commission de la Coopération au Développement of Belgium PRD-Peru 2014-2019Estado de São Paulo FAPESP 05/51988-0Estado de São Paulo FAPESP 07/51199-0Estado de São Paulo FAPESP 16/50108-0European Commission FP7 ELAC2015/T08-1061FONDECYT, Peru 008-2014Ministry of Health of Brazil 404067/2012-3
6 · The paper itself

Abstract

backgroundETRAMP11.2 (PVX_003565) is a well-characterized protein with antigenic potential. It is considered to be a serological marker for diagnostic tools, and it has been suggested as a potential vaccine candidate. Despite its immunological relevance, the polymorphism of the P. vivax ETRAMP11.2 gene (pvetramp11.2) remains undefined. The genetic variability of an antigen may limit the effectiveness of its application as a serological surveillance tool and in vaccine development and, therefore, the aim of this study was to investigate the genetic diversity of pvetramp11.2 in parasite populations from Amazonian regions and worldwide. We also evaluated amino acid polymorphism on predicted B-cell epitopes. The low variability of the sequence encoding PvETRAMP11.2 protein suggests that it would be a suitable marker in prospective serodiagnostic assays for surveillance strategies or in vaccine design against P. vivax malaria.

methodsThe pvetramp11.2 of P. vivax isolates collected from Brazil (n = 68) and Peru (n = 36) were sequenced and analyzed to assess nucleotide polymorphisms, allele distributions, population differentiation, genetic diversity and signature of selection. In addition, sequences (n = 104) of seven populations from different geographical regions were retrieved from the PlasmoDB database and included in the analysis to study the worldwide allele distribution. Potential linear B-cell epitopes and their polymorphisms were also explored.

resultsThe multiple alignments of 208 pvetramp11.2 sequences revealed a low polymorphism and a marked geographical variation in allele diversity. Seven polymorphic sites and 11 alleles were identified. All of the alleles were detected in isolates from the Latin American region and five alleles were detected in isolates from the Southeast Asia/Papua New Guinea (SEA/PNG) region. Three alleles were shared by all Latin American populations (H1, H6 and H7). The H1 allele (reference allele from Salvador-1 strain), which was absent in the SEA/PNG populations, was the most represented allele in populations from Brazil (54%) and was also detected at high frequencies in populations from all other Latin America countries (range: 13.0% to 33.3%). The H2 allele was the major allele in SEA/PNG populations, but was poorly represented in Latin America populations (only in Brazil: 7.3%). Plasmodium vivax populations from Latin America showed a marked inter-population genetic differentiation (fixation index [Fst]) in contrast to SEA/PNG populations. Codon bias measures (effective number of codons [ENC] and Codon bias index [CBI]) indicated preferential use of synonymous codons, suggesting selective pressure at the translation level. Only three amino acid substitutions, located in the C-terminus, were detected. Linear B-cell epitope mapping predicted two epitopes in the Sal-1 PvETRAMP11.2 protein, one of which was fully conserved in all of the parasite populations analyzed.

conclusionsWe provide an overview of the allele distribution and genetic differentiation of ETRAMP11.2 antigen in P. vivax populations from different endemic areas of the world. The reduced polymorphism and the high degree of protein conservation supports the application of PvETRAMP11.2 protein as a reliable antigen for application in serological assays or vaccine design. Our findings provide useful information that can be used to inform future study designs.

Indexed as

Malaria, VivaxPlasmodium vivaxAntigens, ProtozoanEpitopes, B-LymphocyteGenetic VariationHumansMembrane ProteinsProspective StudiesProtozoan ProteinsSequence Analysis, DNAAntigens, ProtozoanEpitopes, B-LymphocyteMembrane ProteinsProtozoan ProteinsAntigenGenetic variationPlasmodium vivaxPolymorphismPvETRAMP11.2

Identifiers

PMID37461081
PMCPMC10353105
OpenAlexW4384561608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.